A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Official Title

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Summary:

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Trial Description

Primary Outcome:

• Median progression free survival (mPFS)

• Trough observed serum concentration (Ctrough)
• Objective response rate (ORR)
• Median duration of response (MDOR)
• Overall survival rate (OSR)
• Incidence of Adverse Events (AE)
• Incidence of Serious Adverse Events (SAE)
• Incidence of death
• Incidence of laboratory abnormalities
• Incidence of Adverse Events (AE) leading to discontinuation

View this trial on ClinicalTrials.gov